AMERISOURCEBERGEN CORP : Other Events (form 8-K)

Published: 2022-07-01 16:05:06 ET ABC

Item 8.01. Other Events.

On June 27, 2022, AmerisourceBergen Corporation (the "Company") and two other national pharmaceutical distributors entered into an agreement with the State of Oklahoma to resolve opioid-related claims. Pursuant to the agreement, the three distributors will pay up to approximately $308 million, including attorneys' fees and costs, to the State of Oklahoma and its participating subdivisions. This amount is consistent with Oklahoma's allocation under the previously announced comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities. Upon effectiveness of the Oklahoma settlement, the State of Oklahoma will dismiss its lawsuit against the distributors with prejudice. The agreement is subject to certain contingencies, including attaining the required rate of subdivision participation by September 23, 2022.

While the Company strongly disputes the allegations made in the complaints filed by the State of Oklahoma and its political subdivisions, it believes that resolving all of such litigation will further its goal of achieving broad resolution of governmental opioid claims while delivering meaningful relief to communities across the United States that have been impacted by the opioid epidemic.

Cautionary Statements Regarding Forward Looking Statements

The preceding descriptions of the resolution of certain opioids-related claims against the Company constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the Company undertakes no obligation to publicly update forward-looking statements. Investors should read the important risk factors described in the Company's Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission.

--------------------------------------------------------------------------------